Peter
A. Netland and the Travoprost Study Group
University of Tennessee Health Science Center, Memphis, TN,
USA
Purpose:
Determine the safety and efficacy of travoprost (0.0015% and
0.004%)
compared to latanoprost 0.005% and timolol 0.5% for lowering
intraocular pressure in patients with open-angle
glaucoma (OAG) or ocular hypertension (OH). Methods:
Eight-hundred one patients with OAG or OH received either travoprost
0.0015%, travoprost 0.004%, latanoprost 0.005%, QD, or timolol 0.5%, BID.
Results: Combined results
indicate the IOP-lowering efficacy of travoprost was enhanced over the day from
8 AM to 4 PM. Mean IOP reductions
for travoprost 0.004% were 0.8mmHg (p=0.0191) greater than for latanoprost
0.005% at 4 PM. Travoprost 0.004%
was superior to timolol 0.5% in lowering IOP, when data were pooled over
visits, with mean IOP ranging from 17.7 to 19.1 mmHg for travoprost 0.004%
compared to 19.4 to 20.3 mmHg for timolol 0.5%. All treatment groups experienced none/trace to mild
hyperemia (0-1 on a scale of 0-3). Iris pigmentation changes occurred in 3.1%
of patients in the travoprost 0.004% group compared to 5.2% in the latanoprost
0.005% group. No serious, related
adverse events were reported for any therapy. Conclusions: When used as primary therapy, travoprost 0.004%
was superior or equal to latanoprost 0.005% and superior to timolol 0.5% in the
reduction of IOP in patients with open-angle glaucoma and ocular
hypertension. Travoprost was safe
and well tolerated.
The study was supported by Alcon Research, Ltd.